Table I.
Baseline clinical characteristics and demographics of patients undergoing PCI with TH versus IR2.5.
| TandemHeart (n = 32) | Impella 2.5 (n = 36) | All patients (n = 68) | P value for between group comparison | |
|---|---|---|---|---|
|
| ||||
| Age (y) 1 | 70.1 ± 12.1 | 71.9 ± 12.2 | 71.1 ± 12.1 | 0.55 |
|
| ||||
| Male sex2 | 24/32 (75%) | 25/36 (69%) | 49/68 (72%) | 0.79 |
|
| ||||
| Cardiovascular risk factors | ||||
|
| ||||
| Diabetes2 | 15/32 (47%) | 17/36 (47%) | 32/68 (47%) | 1.0 |
|
| ||||
| Hypertension2 | 27/32 (84%) | 33/36 (92%) | 60/68 (88%) | 0.46 |
|
| ||||
| Dyslipidemia2 | 27/32 (84%) | 34/36 (94%) | 61/68 (90%) | 0.24 |
|
| ||||
| Positive family history2 | 15/32 (47%) | 16/36 (44%) | 31/68 (46%) | 1.0 |
|
| ||||
| Current Smoking2 | 4/32 (13%) | 4/36 (11%) | 8/68 (12%) | 1.0 |
|
| ||||
| BMI (kg. m2)1 | 29.5 ± 6.8 | 27.1 ± 5.6 | 28.2 ± 6.2 | 0.12 |
|
| ||||
| Serum creatinine (mg/dL)1 | 1.4 ± 1.4 | 1.2 ± 0.6 | 1.3 ± 1.0 | 0.35 |
|
| ||||
| GFR (ml/min)1 | 73.8 ± 42.1 | 67.9 ± 31.6 | 70.6 ± 36.6 | 0.52 |
|
| ||||
| Cardiac Status | ||||
|
| ||||
| Baseline systolic BP (mmHg)1 | 121 ± 25 | 126 ± 27 | 124 ± 27 | 0.57 |
|
| ||||
| Baseline MAP (mmHg)1 | 87 ± 15 | 83 ± 18 | 85 ± 17 | 0.35 |
|
| ||||
| Baseline LVEDP (mmHg)1 | 19 ± 10 | 19 ± 7 | 19 ± 8 | 0.94 |
|
| ||||
| LVEF (%)1 | 35.7 ± 18.2 | 26.9 ± 6.0 | 31.0 ± 13.8 | 0.02 |
|
| ||||
| Prior CABG2 | 5/32 (16%) | 9/36 (25%) | 14/68 (21%) | 0.38 |
|
| ||||
| Left Main Disease2 | 7/32 (22%) | 11/36 (31%) | 18/68 (26%) | 0.58 |
|
| ||||
| Unstable presentation2,* | 15/32 (47%) | 19/36 (54%) | 34/68 (50%) | 0.79 |
|
| ||||
| Number of diseased coronary vessels3 | 1 = 4 patients | 1 = 2 patients | 1 = 6 patients | 0.031 |
| 2 = 13 patients | 2 = 6 patients | 2 = 19 patients | ||
| 3 = 15 patients | 3 = 28 patients | 3 = 43 patients | ||
| Mean: 2.3 ± 0.7 | Mean: 2.7 ± 0.6 | Mean: 2.5 ± 0.7 | ||
|
| ||||
| STS risk score | ||||
|
| ||||
| STS risk mortality | 3.5 ± 3.5 | 4.7 ± 3.8 | 4.2 ± 3.7 | 0.19 |
|
| ||||
| STS morbidity & mortality | 21.2 ± 13.8 | 25.1 ± 12.9 | 23.3 ± 13.4 | 0.24 |
|
| ||||
| Medication usage | ||||
|
| ||||
| Aspirin2 | 29/32 (91%) | 31/36 (86%) | 60/68 (88%) | 0.71 |
|
| ||||
| Plavix2 | 24/32 (75%) | 27/36 (75%) | 51/68 (75%) | 1.0 |
|
| ||||
| ACEI/ARB2 | 22/32 (69%) | 23/36 (64%) | 45/68 (66%) | 0.80 |
|
| ||||
| β-blocker2 | 25/32 (78%) | 33/36 (92%) | 58/68 (85%) | 0.17 |
|
| ||||
| Calcium Channel Blocker2 | 5/32 (16%) | 4/36 (11%) | 9/68 (13%) | 0.74 |
|
| ||||
| Nitrates (long acting)2 | 9/32 (28%) | 13/36 (36%) | 22/68 (32%) | 0.61 |
|
| ||||
| Diuretic2 | 9/32 (28%) | 24/36 (67%) | 33/68 (49%) | 0.02 |
|
| ||||
| Lipid Lowering Agent2 | 26/32 (81%) | 32/36 (89%) | 58/68 (85%) | 0.50 |
Data is presented as mean ± SD or number of subjects (%).
Abbreviations not previously defined: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; GFR, glomerular filtration rate (calculated by Cockcroft-Gault formula); LVEDP, left ventricular end diastolic pressure; MAP, mean arterial pressure.
Statistical analyses used:
1
2-sided non-paired Student’s t test,
2
2-sided Fisher’s exact test,
3
Chi-square test.
*
Presentation with unstable angina or non-ST segment elevation MI.